Copyright: ©Author(s) 2026.
World J Diabetes. Apr 15, 2026; 17(4): 115437
Published online Apr 15, 2026. doi: 10.4239/wjd.v17.i4.115437
Published online Apr 15, 2026. doi: 10.4239/wjd.v17.i4.115437
Figure 6 Inhibition of the EP300-nephrocystin-4 axis affects renal fibrosis markers in HK-2 cells.
A-C: Representative western blot images and quantitative analysis of alpha-smooth muscle actin and fibronectin protein levels in nephrocystin-4-knockdown cells; D-F: Representative western blot images and quantitative analysis of alpha-smooth muscle actin and fibronectin protein levels in nephrocystin-4-overexpressing cells. Data are presented as mean ± SD (n = 3). aP < 0.05, bP < 0.01, and cP < 0.001. α-SMA: Alpha-smooth muscle actin; HG: High glucose; NPHP4-OE: Overexpression of nephrocystin-4; siNPHP4: Small interfering RNA targeting nephrocystin-4.
- Citation: Si W, Dai Y, Hu GP, Zhang Q, Lv F, Zhang Q. EP300 drives renal fibrosis in diabetic nephropathy via histone acetyltransferase-mediated nephrocystin-4 expression. World J Diabetes 2026; 17(4): 115437
- URL: https://www.wjgnet.com/1948-9358/full/v17/i4/115437.htm
- DOI: https://dx.doi.org/10.4239/wjd.v17.i4.115437